GEN1

Across TCGA pan-cancer cohorts, GEN1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GEN1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GEN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GEN1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where GEN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.366	0.889	.008	19	view →
LSCC	DFS	Median	II,III,IV	0.969	0.879	.017	8	view →
LUAD	DFS	Tertile	III,IV	0.928	0.392	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GEN1–PDAC (DFS)

Open the PDAC breakdown →